Omega-3 fatty acids in bipolar disorder: Clinical and research considerations

Prostaglandins Leukotrienes and Essential Fatty Acids

Volumn 75, Issue 4-5, 2006, Pages 315-321

  Marangell, Lauren B ^a,b   Suppes, Trisha ^c   Ketter, Terence A ^d   Dennehy, Ellen B ^e   Zboyan, Holly ^a,b   Kertz, Barbara ^a,b   Nierenberg, Andrew ^f   Calabrese, Joseph ^g   Wisniewski, Stephen R ^h   Sachs, Gary ^f  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

^b DEPARTMENT OF VETERANS AFFAIRS   (United States)

^c UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^d STANFORD UNIVERSITY   (United States)

^e PURDUE UNIVERSITY   (United States)

^f MASSACHUSETTS GENERAL HOSPITAL   (United States)

^g CASE WESTERN RESERVE UNIVERSITY   (United States)

^h UNIVERSITY OF PITTSBURGH GRADUATE SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

OMEGA 3 FATTY ACID; PLACEBO;

ARTICLE; BIPOLAR DISORDER; BIPOLAR I DISORDER; BIPOLAR II DISORDER; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG CONCENTRATION; DRUG MECHANISM; DRUG TOLERABILITY; FEMALE; HUMAN; MONOTHERAPY; PREFRONTAL CORTEX; PREGNANCY; PRIORITY JOURNAL; PSYCHOSOCIAL CARE; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME;

ADULT; BIPOLAR DISORDER; DOUBLE-BLIND METHOD; FATTY ACIDS, OMEGA-3; FEASIBILITY STUDIES; FEMALE; HUMANS; PILOT PROJECTS; PLACEBOS; PREGNANCY; PREGNANCY OUTCOME;

EID: 33748969317     PISSN: 09523278     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.plefa.2006.07.008     Document Type: Article

References (60)

1. Kessler R.C., Berglund P., Demler O., Jin R., and Walters E.E. Lifetime prevalence and age-of-onset distributions of DSM-IV disorders in the National Comorbidity Survey Replication. Arch. Gen. Psychiatry 62 6 (2005) 593-602
2. Kashner T.M., Suppes T., Rush A.J., and Altshuler K.Z. Measuring use of outpatient care among mentally ill individuals: a comparison of self reports and provider records. Eval. Program Plann. 22 1 (1999) 31-39
3. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorder. DSM-IV-TR, (2000), Washington, DC, American Psychiatric Association
4. Goodwin F.K., and Jamison K.R. Manic Depressive Illness (1990), Oxford University Press, New York
5. Sperling R.I., Benincaso A.I., Knoell C.T., et al. Dietary omega-3 polyunsaturated fatty acids inhibit phosphoinositide formation and chemotaxis in neutrophils. J. Clin. Invest. 91 2 (1993) 651-660
6. Stoll A.L., Severus W.E., Freeman M.P., et al. Omega-3 fatty acids in bipolar disorder: a preliminary double-blind, placebo-controlled trial. Arch. Gen. Psychiatry 56 5 (1999) 407-412
7. Mirnikjoo B., Brown S.E., Seung-Kim H.F., et al. Protein kinase inhibition by omega-3 fatty acids. J. Biol. Chem. 276 14 (2001) 10888-10896
8. Rapoport S.I., and Bosetti F. Do lithium and anticonvulsants target the brain arachidonic acid cascade in bipolar disorder. Arch. Gen. Psychiatry 59 7 (2002) 592-596
9. Casebolt T.L., and Jope R.S. Long-term lithium treatment selectively reduces receptor-coupled inositol phospholipid hydrolysis in rat brain. Biol. Psychiatry 25 (1989) 329-340
10. Casebolt T.L., and Jope R.S. Effects of chronic lithium treatment on protein kinase C and cyclic AMP dependent protein phosphorylation. Biol. Psychiatry 29 (1991) 33-243
11. Speizer L.A., Watson M.J., and Brunton L.L. Differential effects of omega-3 fish oils on protein kinase activities in vitro. Am. J. Physiol. 261 (1991) E109-E114
12. Holian O., and Nelson R. Action of long-chain fatty acids on protein kinase C activity: comparison of omega-7 and omega-3 fatty acids. Anticancer Res. 12 (1992) 975-980
13. Lenox R.H., Watson D.G., Patel J., and Ellis J. Chronic lithium administration alters a prominent PKC substrate in rat hippocampus. Brain Res. 570 (1992) 333-340
14. Manji H.K., Etcheberrigaray R., Chen G., and Olds J.L. Lithium decreases membrane-associated protein kinase C in hippocampus: selectivity for the alpha isozyme. J. Neurochem. 61 (1993) 2303-2310
15. Manji H.K., Chen G., Hsiao J.K., Risby E.D., Masana M.I., and Potter W.Z. Regulation of signal transduction pathways by mood-stabilizing agents: implications for the delayed onset of therapeutic efficacy. J. Clin. Psychiatry 57 (1996) 34-46
16. Manji H.K., Bebchuk J.M., Moore G.J., Glitz D., Hasanat K.A., and Chen G. Modulation of CNS signal transduction pathways and gene expression by mood-stabilizing agents: therapeutic implications. J. Clin. Psychiatry 60 suppl 2 (1999) 27-39
17. Chen G., Manji H.K., Hawver D.B., Wright C.B., and Potter W.Z. Chronic sodium valproate selectively decreases protein kinase C alpha and epsilon in vitro. J. Neurochem. 63 (1994) 2361-2364
18. Bitran J.A., Manji H.K., Potter W.Z., and Gusovsky F. Down-regulation of PKC alpha by lithium in vitro. Psychopharmacol. Bull. 31 2 (1995) 449-452
19. Kim F.A., Sing A., and Kaneko T. The vHNF1 homeodomain protein establishes early rhombomere identity by direct regulation of Kreisler expression. Mech. Dev. 122 12 (2005) 1300-1309
20. Noaghiul S., and Hibbeln J.R. Cross-national comparisons of seafood consumption and rates of bipolar disorders. Am. J. Psychiatry 160 12 (2003) 2222-2227
21. Edwards R., Peet M., Shay J., and Horrobin D. Omega-3 polyunsaturated fatty acid levels in the diet and in red blood cell membranes of depressed patients. J. Affect. Disorders 48 2-3 (1998) 149-155
22. Hibbeln J.R. Fish consumption and major depression. Lancet 351 9110 (1998) 1213
23. Hibbeln J.R. Long-chain polyunsaturated fatty acids in depression and related conditions. In: Peet M., Glen I., and Horrobin D.F. (Eds). Phospholipid Spectrum Disorder in Psychiatry (1999), Marius Press, Carnforth, England 195-210
24. Hirayama T. Life-Style and Mortality. A Large-Scale Census-Based Cohort Study in Japan. Contributions to Epidemiology and Biostatistics (1990), S. Karger Publishing, Basel, Switzerland
25. Tanskanen A., Tuomilehto J., and Viinamaki H. Cholesterol, depression and suicide. Br. J. Psychiatry 176 (2000) 398-399
26. Tanskanen A., Hibbeln J.R., Hintikka J., Haatainen K., Honkalampi K., and Viinamaki H. Fish consumption, depression, and suicidality in a general population. Arch. Gen. Psychiatry 58 5 (2001) 512-513
27. Tanskanen A., Hibbeln J.R., Tuomilehto J., et al. Fish consumption and depressive symptoms in the general population in Finland. Arch. Gen. Psychiatry 52 4 (2001) 529-531
28. Chiu C.C., Huang S.Y., Su K.P., et al. Polyunsaturated fatty acid deficit in patients with bipolar disorder. Eur. Neuropsychopharmacol. 13 2 (2003) 99-103
29. Sobczak S., Honig A., Christophe A., et al. Lower high-density lipoprotein cholesterol and increased omega-6 polyunsaturated fatty acids in first-degree relatives of bipolar patients. Psychol. Med. 34 1 (2004) 103-112
30. McNamara R.K., Hahn C.G., Richtand N.M., Jandacek R.J., and Tso P. Reductions in the principle brain omega-3 fatty acid, docosahexaenoic acid, in postmortem prefrontal cortex of patients with schizophrenia, bipolar disorder, and major depressive disorder, but not multiple sclerosis or Alzheimer's disease. Biol. Psychiatry 59 (2006) S30
31. Mahadik S.P., Mukherjee S., Horrobin D.F., Jenkins K., Correnti E.E., and Scheffer R.E. Plasma membrane phospholipids fatty acid composition of cultured skin fibroblasts from schizophrenic patients: comparison with bipolar patients and normal subjects. Psychiatry Res. 63 (1996) 133-142
32. Ranjekar P.K., Hinge A., Hegde M.V., Ghate M., Kale A., et al. Decreased antioxidant enzymes and membrane essential polyunsaturated fatty acids in schizophrenic and bipolar mood disorder patients. Psychiatry Res. 121 (2003) 109-122
33. Frangou S., Lewis M., and McCrone P. Efficacy of ethyl-eicosapentaenoic acid in bipolar depression: randomised double-blind placebo-controlled study. Br. J. Psychiatry 188 (2006) 46-50
34. Osher Y., Bersudsky Y., and Belmaker R.H. Omega-3 eicosapentaenoic acid in bipolar depression: report of a small open-label study. J. Clin. Psychiatry 66 6 (2005) 726-729
35. Sagduyu K., Dokucu M.E., Eddy B.A., Craigen G., Baldassano C.F., and Yildiz A. Omega-3 fatty acids decreased irritability of patients with bipolar disorder in an add-on, open label study. Nutr. J. 4 (2005) 1-6
36. Hirashima F., Parow A.M., Stoll A.L., Demopulos C.M., Damico K.E., Rohan M.L., et al. Omega-3 fatty acid treatment and T(2) whole brain relaxation times in bipolar disorder. Am. J. Psychiatry 161 10 (2004) 1922-1924
37. P.E.,Jr. Keck, J. Mintz, S.L. McElroy, M.P. Freeman, T. Suppes, M.A. Frye, L.L. Altshuler, R. Kupka, W.A. Nolen, G.S. Leverich, K.D. Denicoff, H. Grunze, N. Duan, R.M. Post, Double-blind, randomized, placebo-controlled trials of ethyl-eicosapentanoate in the treatment of bipolar depression and rapid cycling bipolar disorder, Biol. Psychiatry, in press.
38. Kinrys G. Hypomania associated with omega-3 fatty acids [letter]. Arch. Gen. Psychiatry 57 (2000) 715-716
39. Baldessarini R.J., Tondo L., Faedda G.L., Suppes T.R., Floris G., and Rudas N. Effects of the rate of discontinuing lithium maintenance treatment in bipolar disorders. J. Clin. Psychiatry 7 10 (1996) 441-448
40. Faedda G.L., Tondo L., Baldessarini R.J., Suppes T., and Tohen M. Outcome after rapid vs. gradual discontinuation of lithium treatment in bipolar disorders. Arch. Gen. Psychiatry 50 6 (1993) 448-455
41. Suppes T., Baldessarini R.J., Faedda G.L., and Tohen M. Risk of recurrence following discontinuation of lithium treatment in bipolar disorder. Arch. Gen. Psychiatry 48 (1991) 1082-1088
42. Centers for disease control: valproate: a new cause of birth defects-report from Italy and follow-up from France. Morb. Mort. Weekly Rep. 32 (1983) 438-439
43. Cohen L.S., Friedman J.M., Jefferson J.W., Johnson E.M., and Weiner M.L. A re-evaluation of risk of in utero exposure to lithium. JAMA 271 (1994) 146-150
44. Rosa F.W. Spina bifida in infants of women treated with carbamazepine during pregnancy. N. Engl. J. Med. 324 (1991) 674-677
45. Viguera A.C., Nonacs R., Cohen L.S., Tondo L., Murray A., and Baldessarini R.J. Risk of recurrence of bipolar disorder in pregnant and nonpregnant women after discontinuing lithium maintenance. Am. J. Psychiatry 157 (2000) 179-184
46. Crawford M.A., Hassam A.G., and Stevens P.A. Essential fatty acid requirements in pregnancy and lactation with special reference to brain development. Prog. Lipid Res. 20 (1981) 31-40
47. Connor W.E., and Neuringer M. The effects of n-3 fatty acid deficiency and repletion upon the fatty acid composition and function of the brain and retina. Prog. Clin. Biol. Res. 282 (1988) 275-294
48. Kubow S., and Koski K.G. Maternal dietary glucose-lipid interactions modulate embryological development in vivo and in embryo culture. Biol. Reprod. 52 1 (1995) 145-155
49. High K.A., and Kubow S. n-3 Fatty acids inhibit defects and fatty acid changes caused by phenytoin in early gestation in mice. Lipids 11 (1994) 771-778
50. Hornstra G., Al M.D., van Houwelingen A.C., and Foreman-van Drongelen M.M. Essential fatty acids in pregnancy and early human development. Eur. J. Obstet. Gynecol. Reprod. Biol. 61 1 (1995) 57-62
51. Glozman S., Green P., Kamensky B., Weiner L., and Yavin E. Ethyl docosahexaenoic acid administration during intrauterine life enhances prostanoid production and reduces free radicals generation in the fetal rat brain. Lipids 34 Suppl (1999) S247-S248
52. Holman R.T., Johnson S.B., and Ogburn P.L. Deficiency of essential fatty acids and membrane fluidity during pregnancy and lactation. Proc. Natl. Acad. Sci. 88 (1991) 4835-4839
53. Min Y., Ghebremeskel K., Crawford M.A., et al. Pregnancy reduces arachidonic and docosahexaenoic in plasma triacylglycerols of Korean women. Int. J. Vitam. Nutr. Res. 70 (2000) 70-75
54. Otto S.J., van Houwelingen A.C., Antal M., et al. Maternal and neonatal essential fatty acid status in phospholipids: an international comparative study. Eur. J. Clin. Nutr. 51 (1997) 232-242
55. Hibbeln J.R., and Salem Jr. N. Dietary polyunsaturated fatty acids and depression: when cholesterol does not satisfy. Am. J. Clin. Nutr. 62 (1995) 1-9
56. Benisek D., Shabert J., and Skornik R. Dietary intake of polyunsaturated fatty acids by pregnant or lactating women in the United States. Obstet. Gynecol. 95 (2000) 77-78
57. Glueck C.J., Streicher P., Wang P., Sprecher D., and Falko J.M. Treatment of severe familial hypertriglyceridemia during pregnancy with very-low-fat diet and n-3 fatty acids. Nutrition 12 (1996) 202-205
58. Bulstra-Ramakers M.T., Huisjes H.J., and Visser G.H. The effects of 3 g eicosapentaenoic acid daily on recurrence of intrauterine growth retardation and pregnancy induced hypertension. Br. J. Obstet. Gynaecol. 102 2 (1995) 123-126
59. Onwude J.L., Lilford R.J., Hjartardottir H., Staines A., and Tuffnell D. A randomized double blind placebo controlled trial of fish oil in high risk pregnancy. Br. J. Obstet. Gynecol. 102 2 (1995) 95-100
60. Sachs G.S., Thase M.E., Otto M.W., et al. Rationale, design, and methods of the systematic treatment enhancement program for bipolar disorder (STEP-BD). Biol. Psychiatry 53 (2003) 1028-1042